About HanzBio
Hanz Bio focuses on the development of novel RNA drug delivery systems. With proprietary patented technology, committed to addressing issues such as high patent barriers, high synthesis difficulty, low delivery efficiency, and poor extrahepatic targeting. Leveraging Hanz Bio's professional expertise in the development of lipid nanoparticles (LNPs), ready to enhance the efficacy of your advanced therapies at any time.
0
k+
Cationic lipid
0
+
Partners
0
+
LNP Technology Platform
Continuous innovation and constant breakthroughs
——
2024.03
Selected for the "Entrepreneurial Leading Talent Project" of Suzhou Industrial Park Received high recognition from the Ministry of Science and Technology for our technical route and team capabilities
2024.10
Recognized as "U45 Influential Youth Award" from CBIITA Led by Chinese and foreign academicians, this selection aims to identify the backbone of the future development of China's biomedicine.
2025.08
In collaboration with ALFA CHEMISTRY (United States) Accelerate the globalization of LNP
2026.01
Hanz Biotechnology (Suzhou) Co., Ltd. was officially established Build a leading LNP drug delivery platform and first-class RNA innovative drug development
2024.08
A number of core invention patents have been submitted and accepted Build intellectual property barriers around LNP structural design and delivery efficiency
2024.12
Recognized as a "Technology-based Small and Medium-sized Enterprise" in Jiangsu Province for the year 2025 The continuous research and development as well as commercialization of LNP platform technology have been highly recognized.
2025.12
LNP core patent authorization The first "one-step" synthesis of lipids to facilitate CAR-T delivery in vivo
Partially published papers
As the first (including co-first) author, published in Nat. Chem., Nat. Nanotech., Nat. Mater., Nat. Commun. More than 20 papers have been published in journals such as. The total citation count exceeds 6,000+.

2023.6.26 nature nanotechnology

Abstract: This study developed an adjuvant-type lipid. By replacing a portion of the ionizable lipid in LNP, it not only enhanced the mRNA delivery efficiency but also endowed LNP with Toll-like receptor 7/8 (TLR7/8) agonistic activity, thereby significantly boosting the immune response of mRNA vaccines while maintaining good tolerability.

2024.2.26 nature communication

This study presents a novel strategy for the synthesis of degradable branched lipids based on a "one-pot" approach. By in-situ construction, it enables the rapid and combinatorial expansion of lipid structures, which not only boosts the mRNA delivery efficiency by up to three orders of magnitude but also significantly simplifies the synthesis process, greatly enhancing production efficiency and effectively reducing the costs of synthesis and screening.

2024.7.9 nature chemistry

This study developed a one-pot sequential multi-component reaction strategy that enables the rapid and efficient synthesis of structurally diverse biodegradable lipid molecules at room temperature. This method significantly simplifies the traditional lipid synthesis process and achieves high-throughput and low-cost combinatorial construction. The lipid library constructed based on this strategy reveals key structural-functional relationships and significantly improves mRNA delivery efficiency. This synthesis platform provides important support for the discovery and large-scale application of new-generation efficient LNP delivery materials.

2024.11.22 nature biomedical engineering

This study achieved the directed chemical evolution of 3-alkynyl-ionic lipids (A3-lipids) through iterative chemical derivatization and combinatorial chemistry strategies, using the amine-aldol-alkyne coupling reaction. After five rounds of iterative optimization, a variety of asymmetric A3 lipids with high delivery activity and good biodegradability were rapidly obtained, and their performance could be comparable to or even superior to that of the benchmark lipids. The established key structure-activity relationship on this basis provided important guidance for accelerating the development of the next-generation mRNA-LNP delivery system.

Partners